These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 581876)
21. Factors influencing the relationship between labelled triiodothyronine and thyroxine levels in the serum of patients with Graves' disease. Földes J; Gyertyánfy G; Tako J; Bános C; Gesztesi E Endokrinologie; 1973 Jan; 61(1):52-64. PubMed ID: 4739850 [No Abstract] [Full Text] [Related]
22. Inappropriate secretion of thyrotropin: discordance between the suppressive effects of corticosteroids and thyroid hormone. Smallridge RC; Wartofsky L; Dimond RC J Clin Endocrinol Metab; 1979 Apr; 48(4):700-5. PubMed ID: 107182 [No Abstract] [Full Text] [Related]
23. Effect of thyrotropin-releasing hormone on serum thyroid hormones: a study in the patients with untreated and treated Graves' disease and subacute thyroiditis. Sato A; Yamada T; Aizawa T; Ichikawa K; Komiya I; Takasu N; Takemura Y J Clin Endocrinol Metab; 1995 Jul; 80(7):2173-7. PubMed ID: 7608274 [TBL] [Abstract][Full Text] [Related]
24. Hypothyroidism with unusual features following propylthiouracil therapy of Graves' disease. Pittman JG; Maloof F Am J Med Sci; 1972 Dec; 264(6):499-505. PubMed ID: 4119609 [No Abstract] [Full Text] [Related]
25. Pituitary-thyroid regulation in euthyroid patients with Graves' disease previously treated with antithyroid drugs. Buerklin EM; Schimmel M; Utiger RD J Clin Endocrinol Metab; 1976 Aug; 43(2):419-27. PubMed ID: 59733 [TBL] [Abstract][Full Text] [Related]
26. Pattern of serum thyroxine, triiodothyronine and thyrotrophin after treatment of thyrotoxicosis. Bellabarba D; Bénard B; Langlois M Clin Endocrinol (Oxf); 1972 Oct; 1(4):345-53. PubMed ID: 4664297 [No Abstract] [Full Text] [Related]
27. [Determination of serum thyroid-stimulating immunoglobulin and its clinical significance in patients with Graves' disease]. Leng S Zhonghua Yi Xue Za Zhi; 1984 Apr; 64(4):200-2. PubMed ID: 6147186 [No Abstract] [Full Text] [Related]
28. Evaluation of a new chemiluminescence technique for human thyrotropin (BeriLux hTSH): diagnostic value of five immunometric assay methods. Hashimoto T; Matsubara F; Nishibu M; Kawai K Eur J Clin Chem Clin Biochem; 1991 Nov; 29(11):753-7. PubMed ID: 1782283 [TBL] [Abstract][Full Text] [Related]
29. [Clinical significance of elevated serum triiodothyronine to thyroxine ratios in patients with Graves' disease treated with antithyroid drugs]. Takamatsu J Nihon Naibunpi Gakkai Zasshi; 1983 Mar; 59(3):295-303. PubMed ID: 6190686 [No Abstract] [Full Text] [Related]
30. The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism. Tsai WC; Pei D; Wang TF; Wu DA; Li JC; Wei CL; Lee CH; Chen SP; Kuo SW Clin Endocrinol (Oxf); 2005 May; 62(5):521-4. PubMed ID: 15853819 [TBL] [Abstract][Full Text] [Related]
31. Human thyroid stimulating activity and clinical state in antithyroid treatment of juvenile Graves' disease. Takata I; Suzuki Y; Saida K; Sato T Acta Endocrinol (Copenh); 1980 May; 94(1):46-52. PubMed ID: 6247873 [No Abstract] [Full Text] [Related]
33. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. Hashizume K; Ichikawa K; Sakurai A; Suzuki S; Takeda T; Kobayashi M; Miyamoto T; Arai M; Nagasawa T N Engl J Med; 1991 Apr; 324(14):947-53. PubMed ID: 1900575 [TBL] [Abstract][Full Text] [Related]
34. [The effects of plasma exchange upon patients with malignant exophthalmos due to Graves' disease]. Fukino O; Tamai H; Kimura T; Nakagawa T; Inaba S; Kuma K; Kubota K; Kuzuya N; Uchimura H; Nagataki S Nihon Naibunpi Gakkai Zasshi; 1983 Jan; 59(1):72-80. PubMed ID: 6687575 [No Abstract] [Full Text] [Related]
35. Effects of propylthiouracil and methimazole on fetal thyroid status in mothers with Graves' hyperthyroidism. Momotani N; Noh JY; Ishikawa N; Ito K J Clin Endocrinol Metab; 1997 Nov; 82(11):3633-6. PubMed ID: 9360518 [TBL] [Abstract][Full Text] [Related]
36. Thyroid suppression test and outcome of hyperthyroidism treated with antithyroid drugs and triiodothyronine. Yamamoto M; Igarashi T; Kimura S; Tsukamoto S; Togawa K; Ogata E J Clin Endocrinol Metab; 1979 Jan; 48(1):72-7. PubMed ID: 581766 [No Abstract] [Full Text] [Related]
37. Thyroid suppressibility and long-acting thyroid stimulator in thyrotoxicosis. Silverstein GE; Burke G Arch Intern Med; 1970 Oct; 126(4):615-20. PubMed ID: 4097002 [No Abstract] [Full Text] [Related]
38. Methimazole protection against oxidative stress induced by hyperthyroidism in Graves disease. Sewerynek J; Wiktorska J; Nowak D; Lewinski A Endocr Regul; 2000 Jun; 34(2):83-9. PubMed ID: 10911409 [TBL] [Abstract][Full Text] [Related]
39. [Long-acting thyroid stimulator (LATS), thyrotropin (TSH) and the pathogenesis of hyperthyroidism]. Lamberg BA; Gordin A Nord Med; 1968 Dec; 80(49):1651-7. PubMed ID: 5757398 [No Abstract] [Full Text] [Related]
40. Thyrotoxicosis and pregnancy. Asper SP Trans Am Clin Climatol Assoc; 1974; 85():18-23. PubMed ID: 4804092 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]